Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Bottom line: The SYNVEST study suggests psilocybin may alter synaptic density in treatment-resistant depression by interacting with serotonin 2A receptors, though results are preliminary and require further confirmation.

A man in his late 30s sits in a lab in Toronto, waiting for a small injection. He’s been struggling with depression for years, and nothing has worked. This is a test of something different — a psychedelic compound that might be altering the brain’s structure. The question is: does psilocybin change synaptic density — the connections between neurons — in people who have resisted other treatments?

The answer, hidden in a clinical trial that’s not even complete, might challenge what we know about the brain. And it could explain why some people, after taking psilocybin, feel like they’ve seen a new version of themselves.

The Psychedelic Paradox

Scientists have long wondered why some people respond to antidepressants and why others respond to psychedelics like psilocybin. Derived from magic mushrooms, psilocybin has shown promise in treating depression, but the mechanisms behind its effects are still unclear. Most research has focused on the psychological experience — the so-called “trip.” This new trial, though, takes a different approach: it looks at the brain itself.

The SYNVEST study, led by the Centre for Addiction and Mental Health, is the first to combine psilocybin with PET imaging to track how the drug affects synaptic density in people with treatment-resistant depression (TRD). TRD affects around 30% of people with depression — their symptoms don’t improve with standard antidepressants. If psilocybin can change the brain’s wiring in these individuals, it might offer a new way to think about mental health.

But how does psilocybin work? The answer lies in the brain’s serotonin system. The 5-HT2A receptor — a specific serotonin receptor — is thought to be central to the psychedelic experience. Psilocybin binds to these receptors and may promote neuroplasticity — the brain’s ability to rewire itself.

The study’s design is both ambitious and precise. Volunteers receive a low dose of psilocybin (25 mg) along with psychotherapy, and their brains are scanned using PET imaging to detect changes in synaptic density. Risperidone, an antipsychotic that blocks 5-HT2A receptors, is also used to see if it can prevent or alter the effects of psilocybin. This helps determine whether the observed changes are due to psilocybin interacting with the 5-HT2A receptor or something else.

The researchers are looking for a link between synaptic density and the drug’s antidepressant effects. If psilocybin increases synaptic density in people with TRD, it might be helping to rebuild neural connections lost due to depression. But the results are still early — this is a Phase 2 trial, and the data are not in yet.

The Science of Synapses

Synaptic density measures how many synapses — the gaps between neurons where communication happens — are present in a brain region. In healthy brains, these connections are dynamic, forming and pruning in response to experience. In chronic depression, some studies suggest synaptic density may decrease, especially in the prefrontal cortex — a region involved in mood and decision-making.

The idea that psilocybin might increase synaptic density is not new. A 2023 review noted the potential for psychedelics to promote neurogenesis and synaptic plasticity. But most of that research has been observational or based on animal models. The SYNVEST trial is one of the first to use PET imaging to directly measure synaptic density changes in humans.

PET imaging works by detecting a radioactive tracer that binds to specific proteins or receptors in the brain. In this study, the tracer is designed to bind to a protein found in high concentrations in synapses. By measuring how much of the tracer is absorbed in different brain regions, researchers can estimate synaptic density.

The challenge, as the study admits, is that synaptic density is complex and poorly understood. It’s not just about the number of synapses — it’s also about their strength, their connectivity, and the balance between excitation and inhibition. But the ability to image these changes in real time is a major step forward.

The Role of 5-HT2A Receptors

The 5-HT2A receptor is a target for many psychiatric medications, including risperidone. These drugs block the receptor, reducing the intensity of the psychedelic experience. But in this study, risperidone is used to see if it can block the effects of psilocybin on synaptic density.

This is a clever design. If psilocybin’s effects on synaptic density are mediated by the 5-HT2A receptor, then risperidone should be able to prevent or reduce those effects. The researchers are using this to test the hypothesis that the 5-HT2A receptor is a critical mediator of psilocybin’s antidepressant effects.

But the 5-HT2A receptor is not the only player. Other neurotransmitter systems, like dopamine and glutamate, are also involved in mood regulation. The study focuses on the 5-HT2A receptor, but it doesn’t rule out other factors.

The study is also part of a growing field that uses molecular imaging to explore the neurobiological mechanisms of mental illness. A 2026 review in Neuropsychopharmacology highlighted how PET and SPECT imaging are helping to uncover the complex interplay between neurotransmitter systems, inflammation, and neurodegeneration in conditions like late-life depression.

Frequently Asked Questions

Q: Can psilocybin really change the brain?
A: Yes, but the extent and mechanism are still being studied. Early research suggests that psilocybin can alter neural activity and promote synaptic plasticity, but more work is needed to understand how these changes translate into lasting therapeutic effects.

Q: Is psilocybin safe?
A: Psilocybin is generally considered safe in controlled settings, but it can cause intense psychological experiences, including hallucinations and emotional distress. These effects are typically short-lived and manageable with proper support and supervision.

Q: Will this study show that psilocybin is effective for depression?
A: The study is designed to explore the biological mechanisms behind psilocybin’s effects, not to prove its efficacy. However, the results may provide valuable insights into how the drug works and whether it could be used as a new treatment option.

Q: What is synaptic density?
A: Synaptic density refers to the number of synapses — the connections between neurons — in a given area of the brain. It is a measure of the brain’s capacity to communicate and adapt, and it is thought to be affected by conditions like depression.

Q: Why use PET imaging for this study?
A: PET imaging allows researchers to directly measure changes in synaptic density in real time. This is a powerful tool for understanding how drugs like psilocybin affect the brain and how these changes might be linked to mental health outcomes.

Sources

• ¶SYNVEST Study — ClinicalTrials.gov
• ¶Imaging of Brain Structural and Functional Effects in People With Human Immunodeficiency Virus — The Journal of Infectious Diseases
• ¶Molecular Positron Emission Tomography and Single-Photon Emission Computed Tomography Imaging for Understanding the Neurobiological Mechanisms of Electroconvulsive Therapy — Journal of ECT
• ¶Trajectories of late-life depression: insights from molecular imaging — Neuropsychopharmacology

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.